General Oncological Hospital Of Kifissia Agioi Anargyroi
- Address
- lock Available on a paid plan
Non‑small cell lung cancer therapy
The Department of Medical Oncology at General Oncological Hospital Of Kifissia Agioi Anargyroi focuses on developing innovative treatments for non‑small cell lung cancer.
- Combination of targeted agents with chemoradiation
- Integration of immunotherapy after standard treatment
- Optimizing outcomes for stage III disease
Trials aim to improve survival and quality of life by testing new drug combinations and assessing their safety in patients who cannot undergo surgery.
Radiation‑chemotherapy and immunotherapy integration
Research explores how adding immunotherapy to conventional radiation and chemotherapy regimens can enhance tumor control.
- Evaluating sequential versus concurrent treatment schedules
- Assessing response rates in unresectable stage III lung cancer
- Monitoring long‑term tolerability of combined modalities
The goal is to determine whether the addition of agents like Durvalumab after chemoradiation provides a measurable benefit for patients with advanced disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 9 therapeutic areas and 15 of 94 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 91 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 15 by active trials.
- 1AstraZeneca AB2active
lock +14 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB3trials
lock +7 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 173 other sites in Greece
Therapeutic Area Benchmark — Greece
Select a therapeutic area to compare against other sites in Greece.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Greece
Market Share
Country: Greece
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in General Oncological Hospital Of Kifissia Agioi Anargyroi
lock Showing 1 of 31 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Pharmacokinetics of OMN6 in Patients with Acinetobacter baumannii Complex-Induced HABP or VABP | Omnix Medical Ltd. | Phase II | Recruiting | Jul 2026 | — |
IMP list
lock Showing 1 of 94 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Docetaxel | 5 | Unknown | 2020-12-23 | 2026-04-22 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.